一般演題（口演IS）1 clinical trial

[IS-002] Veliparib Combined with Front-line Chemotherapy and as Monotherapy in Japanese Women with High-grade Serous Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Carcinoma（HGSC）

Kimihiko Ito¹, Mika Mizuno², Hidekatsu Nakai³, Hidenori Kato⁴, Shoji Kamiura⁵, Kimio Ushijima⁶, Shoji Nagao⁷, Hirokuni Takano⁸, Masao Okadome⁹, Munetaka Takekuma¹⁰, Hideki Tokunaga¹¹, Satoru Nagase¹², Daisuke Aoki¹³, Robert L. Coleman¹⁴, Minh H. Dinh¹⁵, Danielle Sullivan¹⁵, Hideyuki Hashiba¹⁶, Hao Xiong¹⁵, Noriyuki Katsumata¹⁷, Aikou Okamoto¹⁸ (1.Kansai Rosai Hospital, Hyogo, Japan, 2.Aichi Cancer Center Hospital, Nagoya-shi, Aichi, Japan, 3.Kindai University Faculty of Medicine, Osakasayama-shi, Osaka, Japan, 4.Hokkaido Cancer Center, Sapporo-shi, Hokkaido, Japan, 5.Osaka International Cancer Institute, Osaka-shi, Osaka, Japan, 6.Kurume University Hospital, Kurume-shi, Fukuoka, Japan, 7.Hyogo Cancer Center, Akashi-shi, Hyogo, Japan, 8.Jikei University Kashiwa Hospital, Kashiwa-shi, Chiba, Japan, 9.NHO Kyushu Cancer Center, Fukuoka-shi, Fukuoka, Japan, 10.Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan, 11.Tohoku University Hospital, Sendai-shi, Miyagi, Japan, 12.Yamagata University Hospital, Yamagata-shi, Yamagata, Japan, 13.Keio University Hospital, Shinjuku-ku, Tokyo, Japan, 14.The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 15.AbbVie Inc., North Chicago, IL, USA, 16.AbbVie GK, Tokyo, Japan, 17.Nippon Medical School Musashi Kosugi Hospital, Kawasaki-shi, Kanagawa, Japan, 18.Jikei University Hospital, Minato-ku, Tokyo, Japan)